FRAX-based intervention and assessment thresholds in seven Latin American countries
- 718 Downloads
Age-specific intervention and assessment thresholds were developed for seven Latin American countries. The intervention threshold ranged from 1.2% (Ecuador) to 27.5% (Argentina) at the age of 50 and 90 years, respectively. In the Latin American countries, FRAX offers a substantial advance for the detection of subjects at high fracture risk.
Intervention thresholds are proposed using the Fracture Risk Assessment (FRAX) tool. We recommended their use to calculate the ten-year probability of fragility fracture (FF) in both, men and women with or without the inclusion of bone mineral density (BMD). The purpose of this study is to compute FRAX-based intervention and BMD assessment thresholds for seven Latin American countries in men and women ≥ 40 years.
The intervention threshold (IT) was set at a 10-year probability of a major osteoporotic fracture (MOF) equivalent to a woman with a prior FF and a body mass index (BMI) equal to 25.0 kg/m2 without BMD or other clinical risk factors. The lower assessment threshold was set at a 10-year probability of a MOF in women with BMI equal to 25.0 kg/m2, no previous fracture and no clinical risk factors. The upper assessment threshold was set at 1.2 times the IT.
For the seven LA countries, the age-specific IT varied from 1.5 to 27.5% in Argentina, 3.8 to 25.2% in Brazil, 1.6 up to 20.0% in Chile, 0.6 to 10.2% in Colombia, 0.9 up to 13.6% in Ecuador, 2.6 to 20.0% in Mexico, and 0.7 up to 22.0% in Venezuela at the age of 40 and 90 years, respectively.
In the LA countries, FRAX-based IT offers a substantial advance for the detection of men and women at high fracture risk, particularly in the elderly. The heterogeneity of IT between the LA countries indicates that country-specific FRAX models are appropriate rather than a global LA model.
KeywordsAssessment thresholds FRAX Intervention threshold Latin American countries Osteoporosis Ten-year fracture probability
Compliance with ethical standards
Conflicts of interest
- 1.Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8(1–2):136. https://doi.org/10.1007/s11657-013-0136-1. CrossRefPubMedPubMedCentralGoogle Scholar
- 4.Kanis JA, Harvey NC, Cooper C, Johansson H, Odén A, McCloskey EV, Advisory Board of the National Osteoporosis Guideline Group (2016) A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos 11(1):25. https://doi.org/10.1007/s11657-016-0278-z CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Zanchetta J, Campusano C, Muzzi B (2012) The Latin America regional audit. Epidemiology, costs and burden of osteoporosis in 2012. Report, International Osteoporosis FoundationGoogle Scholar
- 7.Clark P, Cons-Molina F, Deleze M, Ragi S, Haddock L, Zanchetta JR, Jaller JJ, Palermo L, Talavera JO, Messina DO, Morales-Torres J, Salmeron J, Navarrete A, Suarez E, Pérez CM, Cummings SR (2009) The prevalence of radiographic vertebral fractures in Latin American countries: the Latin American Vertebral Osteoporosis Study (LAVOS). Osteoporos Int 20(2):275–282. https://doi.org/10.1007/s00198-008-0657-4 CrossRefPubMedGoogle Scholar
- 8.Kanis JA, Closkey EV, Johansson H, Strom O, Borgstrom F, Oden A, National Osteoporosis Guideline Group (2008) Case finding for the management of osteoporosis with FRAX-assessment and intervention thresholds for the UK. Osteoporos Int 19(10):1395–1408. https://doi.org/10.1007/s00198-008-0712-1 CrossRefPubMedGoogle Scholar
- 9.Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P, Wilkins M, on behalf of the National Osteoporosis Guideline Group (NOGG) (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62(2):105–108. https://doi.org/10.1016/j.maturitas.2008.11.022 CrossRefPubMedGoogle Scholar
- 10.National Institute for Health and Care Excellence NICE Clinical Guideline 146 (2014) Osteoporosis: assessing the risk of fragility fracture. NICE UK. https://www.nice.org.uk/guidance/cg146, Accessed 18 May 2015
- 11.Salud. Diagnóstico y tratamiento de osteoporosis en mujeres posmenopaúsicas (2013) DOI:http://www.cenetec.salud.gob.mx/descargas/gpc/CatalogoMaestro/IMSS_673_13_Osteoporosisenpostmenopausia/673GER.pdf.
- 12.Secretaria de Salud (2017) Proyecto de Norma Oficial Mexicana PROY-NOM-049-SSA2–2017, para la prevención, detección, diagnóstico, tratamiento, control y vigilancia epidemiológica de la osteoporosis. Diario Oficial de la Federación. http://www.dof.gob.mx/nota_detalle.php?codigo=5496348&fecha=06/09/2017, Accessed 11 Sept 2017
- 13.Kanis JA, Odén A, EV MC, Johansson H, Wahl DA, Cooper C, IOF Working Group on Epidemiology and Quality of Life (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 23(9):2239–2256. https://doi.org/10.1007/s00198-012-1964-3 CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Johansson H, Oden A, Johnell O, Jonsson B, de Laet C, Oglesby A, McCloskey EV, Kayan K, Jalava T, Kanis JA (2004) Optimization of BMD measurements to identify high risk groups for treatment—a test analysis. J Bone Miner Res 19(6):906–913. https://doi.org/10.1359/jbmr.2004.19.6.906 CrossRefPubMedGoogle Scholar
- 16.Leslie WD, Majumdar SR, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA, Manitoba Bone Density Program (2012) Hip fracture probability with FRAX usually indicates densitometric osteoporosi: implications for clinical practice. Osteoporos Int 23(1):391–397. https://doi.org/10.1007/s00198-011-1592-3 CrossRefPubMedGoogle Scholar
- 18.Kanis JA, EV MC, Johansson H, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24(1):23–57. https://doi.org/10.1007/s00198-012-2074-y CrossRefPubMedGoogle Scholar
- 19.Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman JA, Fujiwara S, Glüer C, Goltzman D, Hans D, Krieg MA, La Croix A, McCloskey E, Mellstrom D, Melton LJ 3rd, Pols H, Reeve J, Sanders K, Schott AM, Silman A, Torgerson D, van Staa T, Watts NB, Yoshimura N (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046, 8, DOI: https://doi.org/10.1007/s00198-007-0343-y.
- 20.Qaseem A, Forciea MA, RM ML, Denberg TD, Clinical Guidelines Committee of the American College of Physicians (2017) Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 166(11):818–839. https://doi.org/10.7326/M15-1361 CrossRefPubMedGoogle Scholar
- 21.Scottish Intercollegiate Guidelines Network (SIGN) (2015) Management of osteoporosis and the prevention of fragility fractures. Edinburgh: SIGN; 2015. SIGN publication. http://www.sign.ac.uk, 2015. Accessed 11 Sept 2017
- 23.McCloskey EV, Johansson H, Oden A, Harvey NC, Jiang H, Modin S, Fitzpatrick L, Kanis JA (2017) The effect of abaloparatide-SC on fracture risk is independent of baseline FRAX fracture probability: a post hoc analysis of the ACTIVE Study. J Bone Miner Res 32(8):1625–1631. https://doi.org/10.1002/jbmr.3163 CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Shepstone L, Lenaghan E, Cooper C, Clarke S, Fordham R, Gittoes NJ, Harvey IM, Harvey NC, Heawood A, Holland R, Howe A, Kanis J, Marshall T, O'Neill TW, Peters TJ, Redmond NM, Torgerson DJ, McCloskey EV (2017) A randomized controlled trial of screening in the community to reduce fractures in older women—the SCOOP Study. Lancet, in pressGoogle Scholar
- 25.McCloskey EV, Johansson H, Oden A, Austin M, Siris E, Wang A, Lewiecki EM, Lorenc R, Libanati C, Kanis JA (2012) Denosumab reduces the risk of all osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX®. J Bone Miner Res 27(7):1480–1486. https://doi.org/10.1002/jbmr.1606 CrossRefPubMedGoogle Scholar
- 26.Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ 3rd, O'Neill T, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185–1194, 7, DOI: https://doi.org/10.1359/JBMR.050304.